enVVeno Medical Corp
NASDAQ:NVNO

Watchlist Manager
enVVeno Medical Corp Logo
enVVeno Medical Corp
NASDAQ:NVNO
Watchlist
Price: 3.36 USD -0.88%
Market Cap: 58.9m USD

enVVeno Medical Corp
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

enVVeno Medical Corp
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
enVVeno Medical Corp
NASDAQ:NVNO
PP&E Net
$1.3m
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
PP&E Net
$6.8B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
PP&E Net
$3.5B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
PP&E Net
$3.9B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
PP&E Net
$10.6B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
PP&E Net
$4.4B
CAGR 3-Years
37%
CAGR 5-Years
30%
CAGR 10-Years
29%

enVVeno Medical Corp
Glance View

Market Cap
58.9m USD
Industry
Health Care

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 24 full-time employees. The company went IPO on 2018-05-31. The firm is focused on improving the standard of care in the treatment of venous disease. The firm is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

NVNO Intrinsic Value
Not Available

See Also

What is enVVeno Medical Corp's PP&E Net?
PP&E Net
1.3m USD

Based on the financial report for Sep 30, 2024, enVVeno Medical Corp's PP&E Net amounts to 1.3m USD.

What is enVVeno Medical Corp's PP&E Net growth rate?
PP&E Net CAGR 5Y
1%

Over the last year, the PP&E Net growth was -28%. The average annual PP&E Net growth rates for enVVeno Medical Corp have been 13% over the past three years , 1% over the past five years .

Back to Top